Skip to main content
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
40.99
+0.04 (0.10%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Apellis Pharmaceuticals Revenue

In the year 2025, Apellis Pharmaceuticals had annual revenue of $1.00B with 28.46% growth. Apellis Pharmaceuticals had revenue of $199.91M in the quarter ending December 31, 2025, a decrease of -5.94%.

Revenue (ttm)
$1.00B
Revenue Growth
+28.46%
P/S Ratio
5.23
Revenue / Employee
$1,358,298
Employees
739
Market Cap
5.25B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.00B222.42M28.46%
Dec 31, 2024781.37M384.78M97.02%
Dec 31, 2023396.59M321.17M425.83%
Dec 31, 202275.42M8.86M13.31%
Dec 31, 202166.56M-184.08M-73.44%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Caris Life Sciences 812.03M
Corcept Therapeutics 761.41M
TG Therapeutics 616.29M
Mirum Pharmaceuticals 521.31M
Rhythm Pharmaceuticals 189.76M
Xenon Pharmaceuticals 7.50M
CG Oncology 4.04M
CRISPR Therapeutics AG 3.51M
Revenue Rankings

APLS News

More News